SynthesisThe oncologist2015

Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.

Mellissa Hicks et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.